Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
The Cryoport, Inc. (NASDAQ: CYRX) news page on Stock Titan aggregates company announcements, earnings releases, and operational updates related to its role in temperature-controlled supply chain solutions for the life sciences. Cryoport regularly issues news about its performance, infrastructure expansion, and developments across its Life Sciences Services and Life Sciences Products segments.
Recent news has highlighted quarterly financial results, including revenue from continuing operations across Life Sciences Services, BioStorage/BioServices, and Life Sciences Products. The company also reports on metrics such as the number of commercial cell and gene therapies it supports and the global clinical trials that rely on its logistics and storage capabilities.
Operational updates feature the launch and expansion of Global Supply Chain Centers, such as the facility near Paris Charles de Gaulle Airport, which is designed to provide end-to-end, temperature-controlled solutions for biopharma, animal health, and reproductive medicine. Additional news items cover product and technology introductions from MVE Biological Solutions, including dry vapor shippers and integrated condition monitoring systems powered by Tec4med, as well as the MVECloud platform for monitoring cryogenic environments.
Cryoport also publishes news on strategic actions, such as the divestiture of its CRYOPDP specialty courier business and its strategic partnership with DHL, and on quality and compliance milestones, including ISO 21973 certification for transportation of human cells for therapeutic use. Investors and industry observers can use this news feed to follow how Cryoport’s financial performance, infrastructure, and service offerings evolve over time.
Cryoport (NASDAQ: CYRX) reported FY2025 revenue of $176.2 million, up 12% year-over-year and above prior guidance, with Life Sciences Services revenue of $96.5 million (+18%) and Life Sciences Products revenue of $79.7 million (+7%).
The company supported a record 760 clinical trials and 20 commercial therapies, ended FY2025 with $411.2 million in cash and provided 2026 revenue guidance of $190.0M–$194.0M (8%–10% growth).
Cryoport (Nasdaq: CYRX) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026 after U.S. markets close.
Management will issue a review document at 4:05 p.m. ET and host a questions-and-answers conference call at 5:00 p.m. ET with an accompanying slide deck; replay available through March 10, 2026.
Cryoport (NASDAQ: CYRX) launched the MVE Fusion® 800 Series, a lab-sized self-sustaining cryogenic freezer designed for space-constrained environments. The Fusion 800 eliminates the need for a continuous liquid nitrogen supply, delivers steady-state temperatures at or below -150°C, and fits through standard doorways at 32 inches wide. The technology is ISBER award-winning and aimed at research facilities, hospital pharmacies, biorepositories, and blood and tissue banks.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (Nasdaq: CYRX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.
An earnings release and a document titled "Cryoport Third Quarter 2025 in Review" will be issued at 4:05 p.m. ET, followed by a management questions-and-answers conference call at 5:00 p.m. ET the same day. The review document and slide deck will be available in the Investor Relations section at https://ir.cryoportinc.com/news-events/ir-calendar.
The live call dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (International) with conference ID 1120106. A replay will be available online ~three hours after the call and by dial-in until November 11, 2025 (replay numbers: 1-844-512-2921 U.S.; 1-412-317-6671 International).
Cryoport (Nasdaq: CYRX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.
An earnings release and a document titled "Cryoport Third Quarter 2025 in Review" will be issued at 4:05 p.m. ET, followed by a management questions-and-answers conference call at 5:00 p.m. ET the same day. The review document and slide deck will be available in the Investor Relations section at https://ir.cryoportinc.com/news-events/ir-calendar.
The live call dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (International) with conference ID 1120106. A replay will be available online ~three hours after the call and by dial-in until November 11, 2025 (replay numbers: 1-844-512-2921 U.S.; 1-412-317-6671 International).
MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.
The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.